Disease-modifying therapy for multiple sclerosis

Research output: Contribution to journalReview articlepeer-review


Remarkable expansion of new diagnostic criteria and disease-modifying treatments for multiple sclerosis has occurred in the last two decades. Revision of diagnostic criteria and characterization of disease course has allowed earlier diagnosis and better characterization of individual patients. With the current treatment armamentarium in the USA offering 11 agents, patients can now benefit from increasingly individualized therapy. The therapeutic decision-making process has become more complex, with the availability of multiple medications. Relative efficacy, potentially severe adverse events, tolerability issues and patient's preferences must now all be considered so that increasingly disease management more frequently involves physicians with multiple sclerosis subspecialty expertise. This article aims to provide a clinically oriented and concise review of currently available, as well as emerging, disease-modifying treatment therapies in multiple sclerosis.

Original languageEnglish
Pages (from-to)253-279
Number of pages27
JournalFuture Neurology
Issue number3
StatePublished - 1 May 2015


  • disease-modifying treatment
  • efficacy
  • injectable agents
  • intravenous agents
  • multiple sclerosis
  • novel therapies
  • oral agents
  • side effects


Dive into the research topics of 'Disease-modifying therapy for multiple sclerosis'. Together they form a unique fingerprint.

Cite this